DOAC-Remove™ 

For the Removal of DOACs from Plasma Specimens 

DOAC-Remove™ tablets are intended to be used for removal of Direct Oral Anticoagulants (DOACs) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban and edoxaban. It also successfully removes the direct thrombin inhibitor argatroban from plasma samples. DOAC-Remove™ reduces the false positivity for lupus anticoagulants tests on DOAC-containing plasmas and is useful for eliminating interference of DOACs on routine coagulation assays such as APTT, PT, TT, single factors and APC-R. DOAC-Remove™ has no significant effect on coagulation factors. 

-Add one DOAC-Remove™ tablet to about 1 mL (range 0.5 to 2 mL) of citrated plasma 

-Mix gently for 5 minutes 

-Centrifuge for 2 minutes at 2000g 

-The plasma supernatant is now free of DOACs and can be used for immediate coagulation testing or can be frozen in aliquots for future applications 

Reference Product Package
5D-82410-A DOAC-Remove 20 20 tablets
5D-82410-B DOAC-Remove 50 50 tablets
5D-82410-C DOAC-Remove 250 250 tablets